Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Антимюллеров гормон и его прогностическая значимость для оценки качества ооцитов
Антимюллеров гормон и его прогностическая значимость для оценки качества ооцитов
Александрова Н.В. Антимюллеров гормон и его прогностическая значимость для оценки качества ооцитов. Гинекология. 2020; 22 (6): 21–26. DOI: 10.26442/20795696.2020.6.200473
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Аннотация
В статье систематизирована информация о диагностических возможностях современных клинико-лабораторных маркеров овариального резерва. Обсуждены диагностические возможности антимюллерова гормона (АМГ) в качестве маркера овариального резерва, позволяющие проводить подбор дозы гормональных препаратов и прогнозировать ответ яичника на стимуляцию в программах вспомогательных репродуктивных технологий. В работе впервые обсуждается роль АМГ в оценке качества ооцитов и последующих эмбрионов. Несмотря на недостаточные литературные данные, дальнейшее изучение АМГ, а также проведение полномасштабных исследований в данном направлении представляется крайне перспективным.
Ключевые слова: качество ооцитов, стимуляция яичников, овариальный резерв, маркеры, вспомогательные репродуктивные технологии, диагностика.
Key words: oocyte quality, ovarian stimulation, ovarian reserve, markers, assisted reproductive technologies, diagnostics.
Ключевые слова: качество ооцитов, стимуляция яичников, овариальный резерв, маркеры, вспомогательные репродуктивные технологии, диагностика.
________________________________________________
Key words: oocyte quality, ovarian stimulation, ovarian reserve, markers, assisted reproductive technologies, diagnostics.
Полный текст
Список литературы
1. Tal R, Seifer DB. Ovarian reserve testing: a user’s guide. Am J Obstet Gynecol 2017; 217: 129–40.
2. Seifer DB, MacLaughlin DT, Christian BP et al. Early follicular serum mullerian-inhibiting substance levels are associated with ovarian response during assisted reproductive technology cycles. Fertil Steril 2002; 77: 468–71.
3. Depmann M, Eijkemans MJ, Broer SL et al. Does AMH Relate to Timing of Menopause? Results of an Individual Patient Data Meta-Analysis. J Clin Endocrinol Metab 2018; 103 (10): 3593–600. DOI: 10.1210/jc.2018-00724
4. Garg D, Tal R. The role of AMH in the pathophysiology of polycystic ovarian syndrome Reproductive BioMedicine Online 2016; 33 (1): 15–28.
5. La Marca A, Sighinolfi G, Radi D et al. Anti-Mullerian hormone (AMH) as a predictive marker in assisted reproductive technology (ART). Hum Reprod Update 2010; 16: 113–1305.
6. Rajpert-De Meyts E, Jorgensen N, Graem N et al. Expression of anti-Mullerian hormone during normal and pathological gonadal development: association with differentiation of Sertoli and granulosa cells.
J Clin Endocrinol Metab 1999; 84 (10): 3836–44.
7. Durlinger AL, Kramer P, Karels B et al. Control of primordial follicle recruitment by anti-Mullerian hormone in the mouse ovary. Endocrinology 1999; 140: 5789–579.
8. Sowers M, McConnell D, Gast K et al. Anti-Mullerian hormone and inhibin B variability during normal menstrual cycles. Fertil Steril 2010; 94: 1482–6.
9. Dewailly D, Gronier H, Poncelet E et al. Diagnosis of polycystic ovary syndrome (PCOS): revisiting the threshold values of follicle count on ultrasound and of the serum AMH level for the definition of polycystic ovaries. Hum Reprod 2011; 26 (11): 3123–9.
10. Lin YH, Chiu WC, Wu CH et al. Anti-mullerian hormone and polycystic ovary syndrome. Fertil Steril 2011; 96 (1): 230–5.
11. Bedenk J, Vrtačnik-Bokal E, Virant-Klun I. The role of anti-Müllerian hormone (AMH) in ovarian disease and infertility. J Assist Reprod Genet 2020; 37: 89–100.
12. Pacheco A, Cruz M, Iglesias C et al. Very low anti-mullerian hormone concentrations are not an independent predictor of embryo quality and pregnancy rate. Reprod Biomed Online 2018; 37: 113–9.
13. Sunkara SK, Rittenberg V, Raine-Fenning N et al. Association between the number of eggs and live birth in IVF treatment: an analysis of 400 135 treatment cycles. Hum Reprod (Oxford, England) 2011; 26: 1768–74.
14. Sowers MR, McConnell D, Yosef M et al. Relating smoking, obesity, insulin resistance, and ovarian biomarker changes to the final menstrual period. Ann N Y Acad Sci 2010; 1204: 95–103.
15. Dennis NA, Houghton LA, Jones GT et al. The level of serum anti-Mullerian hormone correlates with vitamin D status in men and women but not in boys. J Clin Endocrinol Metab 2012; 97 (7): 2450–5.
16. Seifer DB, Mac Laughlin D, Christian BBA et al. Early follicular serum müllerian-inhibiting substance levels are associated with ovarian response during assisted reproductive technology cycles. Fertil Steril 2002; 77 (3): 468–47.
17. Hayes E, Kushnir V, Ma X et al. Intra-cellular mechanism of anti-Mullerian hormone (AMH) in regulation of follicular development. Mol Cell Endocrinol 2016; 433: 56–65.
18. Назаренко Т.А. Эндокринные факторы женского и мужского бесплодия. Принципы гормонального лечения: монография. М., 2017.
[Nazarenko T.A. Endocrine factors of female and male infertility. Principles of hormonal treatment: monograph. Moscow, 2017 (in Russian).]
19. Broer SL, van Disseldorp J, Broeze KA et al. Added value of ovarian reserve testing on patient characteristics in the prediction of ovarian response and ongoing pregnancy: an individual patient data approach. Hum Reprod Update 2013; 19: 26–36.
20. Arce JC, La Marca A, Mirner Klein B et al. Antimullerian hormone in gonadotropin releasing-hormone antagonist cycles: prediction of ovarian response and cumulative treatment outcome in good-prognosis patients. Fertil Steril 2013; 99: 1644–53.
21. Александрова Н.В., Марченко Л.А. Современные подходы к оценке овариального резерва у женщин с преждевременной недостаточностью яичников (обзор литературы). Проблемы репродукции. 2007; 13 (2): 22–9.
[Aleksandrova N.V., Marchenko L.A. Sovremennye podkhody k otsenke ovarial'nogo rezerva u zhenshchin s prezhdevremennoi nedostatochnost'iu iaichnikov (obzor literatury). Problemy reproduktsii. 2007; 13 (2): 22–9 (in Russian).]
22. La Marca A, Sunkara SK. Individualization of controlled ovarian stimulation in IVF using ovarian reserve markers: from theory to practice. Hum Reprod Update 2014; 20: 124–40.
23. Tarlatzi TB, Venetis CA, Devreker F et al. What is the best predictor of severe ovarian hyperstimulation syndrome in IVF? A cohort study. J Assis Reprod Genet 2017; 34: 1341–51.
24. La Marca A, Sighinolfi G, Radi D et al. Anti-Mullerian hormone (AMH) as a predictive marker in assisted reproductive technology (ART). Hum Reprod Update 2010; 16: 113–30.
25. Broer SL, van Disseldorp J, Broeze KA et al. Added value of ovarian reserve testing on patient characteristics in the prediction of ovarian response and ongoing pregnancy: an individual patient data approach. Hum Reprod Update 2013; 19: 26–36.
26. Melado Vidales L, Fernandez-Nistal A, Martinez Fernandez V et al. Anti-Mullerian hormone levels to predict oocyte maturity and embryo quality during controlled ovarian hyperstimulation. Minerva Ginecol 2017; 69: 225–32.
27. Yao L, Zhang W, Li H et al. The role of serum AMH and FF AMH in predicting pregnancy outcome in the fresh cycle of IVF/ICSI: a meta-analysis. Int J Clin Exp Med 2015; 8: 1755–67.
28. Ebner T, Sommergruber M, Moser M et al. Basal level of anti-Mullerian hormone is associated with oocyte quality in stimulated cycles. Hum Reprod (Oxford, England) 2006; 21: 2022–6.
29. Borges E, Braga D, Setti A et al. The predictive value of serum concentrations of anti-Mullerian hormone for oocyte quality, fertilization, and implantation. JBRA Assist Reprod 2017; 21: 176–82.
30. La Marca A, Minasi MG, Sighinolfi G et al. Female age, serum antimullerian hormone level, and number of oocytes affect the rate and number of euploid blastocysts in in vitro fertilization/intracytoplasmic sperm injection cycles. Fertil Steril 2017; 108: 777.e772–83.e772.
31. Jiang X, Yan J, Sheng Y et al. Low anti-Mullerian hormone concentration is associated with increased risk of embryonic aneuploidy in women of advanced age. Reprod Biomed Online 2018; 37: 178–83.
32. Fanchin R, Mendez Lozano DH, Frydman N et al. Anti-Mullerian hormone concentrations in the follicular fluid of the preovulatory follicle are predictive of the implantation potential of the ensuing embryo obtained by in vitro fertilization. J Clin Endocrinol Metab 2007; 92: 1796–802.
33. Majumder K, Gelbaya TA, Laing I, Nardo LG. The use of anti-Mullerian hormone and antral follicle count to predict the potential of oocytes and embryos. Eur J Obstet Gynecol Reprod Biol 2010; 150: 166–70.
34. De Conto E, Genro VK, da Silva DS et al. AMH as a prognostic factor for blastocyst development. JBRA Assist Reprod 2015; 19: 131–4.
35. Kavoussi SK, Odenwald KC, Boehnlein LM et al. Antimullerian hormone as a predictor of good-quality supernumerary blastocyst cryopreservation among women with levels <1 ng/mL versus 1–4 ng/mL. Fertil Steril 2015; 104: 633–6.
36. Lyttle Schumacher BM, Jukic AM, Steiner AZ. Anti-Mullerian hormone as a risk factor for miscarriage in naturally conceived pregnancies. Fertil Steril 2018; 109: 1065.e1–71.e1.
37. McCormack CD, Leemaqz SY, Furness DL et al. Anti-Mullerian hormone levels in recurrent embryonic miscarriage patients are frequently abnormal, and may affect pregnancy outcomes. J Obstet Gynaecol 2019; 39: 623–7.
38. Tarasconi B, Tadros T, Ayoubi JM et al. Serum anti-Mullerian hormone levels are independently related to miscarriage rates after in vitro fertilization-embryo transfer. Fertil Steril 2017; 108: 518–24.
39. Gleicher N, Kushnir VA, Sen A et al. Definition by FSH, AMH and embryo numbers of good-, intermediate- and poor-prognosis patients suggests previously unknown IVF outcome-determining factor associated with AMH. J Transl Med 2016; 14: 172.
40. Nelson SM, La Marca A. The journey from the old to the new AMH assay: how to avoid getting lost in the values. Reprod Biomed Online 2011; 23 (4): 411–20. DOI: 10.1016/j.rbmo.2011.06.011
41. La Marca A, Tolani AD, Capuzzo M. The interchangeability of two assays for the measurement of anti-Müllerian hormone when personalizing the dose of FSH in in-vitro fertilization cycles. Gynecol Endocrinol 2020; 28: 1–5. DOI: 10.1080/09513590.2020.1810659
2. Seifer DB, MacLaughlin DT, Christian BP et al. Early follicular serum mullerian-inhibiting substance levels are associated with ovarian response during assisted reproductive technology cycles. Fertil Steril 2002; 77: 468–71.
3. Depmann M, Eijkemans MJ, Broer SL et al. Does AMH Relate to Timing of Menopause? Results of an Individual Patient Data Meta-Analysis. J Clin Endocrinol Metab 2018; 103 (10): 3593–600. DOI: 10.1210/jc.2018-00724
4. Garg D, Tal R. The role of AMH in the pathophysiology of polycystic ovarian syndrome Reproductive BioMedicine Online 2016; 33 (1): 15–28.
5. La Marca A, Sighinolfi G, Radi D et al. Anti-Mullerian hormone (AMH) as a predictive marker in assisted reproductive technology (ART). Hum Reprod Update 2010; 16: 113–1305.
6. Rajpert-De Meyts E, Jorgensen N, Graem N et al. Expression of anti-Mullerian hormone during normal and pathological gonadal development: association with differentiation of Sertoli and granulosa cells.
J Clin Endocrinol Metab 1999; 84 (10): 3836–44.
7. Durlinger AL, Kramer P, Karels B et al. Control of primordial follicle recruitment by anti-Mullerian hormone in the mouse ovary. Endocrinology 1999; 140: 5789–579.
8. Sowers M, McConnell D, Gast K et al. Anti-Mullerian hormone and inhibin B variability during normal menstrual cycles. Fertil Steril 2010; 94: 1482–6.
9. Dewailly D, Gronier H, Poncelet E et al. Diagnosis of polycystic ovary syndrome (PCOS): revisiting the threshold values of follicle count on ultrasound and of the serum AMH level for the definition of polycystic ovaries. Hum Reprod 2011; 26 (11): 3123–9.
10. Lin YH, Chiu WC, Wu CH et al. Anti-mullerian hormone and polycystic ovary syndrome. Fertil Steril 2011; 96 (1): 230–5.
11. Bedenk J, Vrtačnik-Bokal E, Virant-Klun I. The role of anti-Müllerian hormone (AMH) in ovarian disease and infertility. J Assist Reprod Genet 2020; 37: 89–100.
12. Pacheco A, Cruz M, Iglesias C et al. Very low anti-mullerian hormone concentrations are not an independent predictor of embryo quality and pregnancy rate. Reprod Biomed Online 2018; 37: 113–9.
13. Sunkara SK, Rittenberg V, Raine-Fenning N et al. Association between the number of eggs and live birth in IVF treatment: an analysis of 400 135 treatment cycles. Hum Reprod (Oxford, England) 2011; 26: 1768–74.
14. Sowers MR, McConnell D, Yosef M et al. Relating smoking, obesity, insulin resistance, and ovarian biomarker changes to the final menstrual period. Ann N Y Acad Sci 2010; 1204: 95–103.
15. Dennis NA, Houghton LA, Jones GT et al. The level of serum anti-Mullerian hormone correlates with vitamin D status in men and women but not in boys. J Clin Endocrinol Metab 2012; 97 (7): 2450–5.
16. Seifer DB, Mac Laughlin D, Christian BBA et al. Early follicular serum müllerian-inhibiting substance levels are associated with ovarian response during assisted reproductive technology cycles. Fertil Steril 2002; 77 (3): 468–47.
17. Hayes E, Kushnir V, Ma X et al. Intra-cellular mechanism of anti-Mullerian hormone (AMH) in regulation of follicular development. Mol Cell Endocrinol 2016; 433: 56–65.
18. Nazarenko T.A. Endocrine factors of female and male infertility. Principles of hormonal treatment: monograph. Moscow, 2017 (in Russian).
19. Broer SL, van Disseldorp J, Broeze KA et al. Added value of ovarian reserve testing on patient characteristics in the prediction of ovarian response and ongoing pregnancy: an individual patient data approach. Hum Reprod Update 2013; 19: 26–36.
20. Arce JC, La Marca A, Mirner Klein B et al. Antimullerian hormone in gonadotropin releasing-hormone antagonist cycles: prediction of ovarian response and cumulative treatment outcome in good-prognosis patients. Fertil Steril 2013; 99: 1644–53.
21. Aleksandrova N.V., Marchenko L.A. Sovremennye podkhody k otsenke ovarial'nogo rezerva u zhenshchin s prezhdevremennoi nedostatochnost'iu iaichnikov (obzor literatury). Problemy reproduktsii. 2007; 13 (2): 22–9 (in Russian).
22. La Marca A, Sunkara SK. Individualization of controlled ovarian stimulation in IVF using ovarian reserve markers: from theory to practice. Hum Reprod Update 2014; 20: 124–40.
23. Tarlatzi TB, Venetis CA, Devreker F et al. What is the best predictor of severe ovarian hyperstimulation syndrome in IVF? A cohort study. J Assis Reprod Genet 2017; 34: 1341–51.
24. La Marca A, Sighinolfi G, Radi D et al. Anti-Mullerian hormone (AMH) as a predictive marker in assisted reproductive technology (ART). Hum Reprod Update 2010; 16: 113–30.
25. Broer SL, van Disseldorp J, Broeze KA et al. Added value of ovarian reserve testing on patient characteristics in the prediction of ovarian response and ongoing pregnancy: an individual patient data approach. Hum Reprod Update 2013; 19: 26–36.
26. Melado Vidales L, Fernandez-Nistal A, Martinez Fernandez V et al. Anti-Mullerian hormone levels to predict oocyte maturity and embryo quality during controlled ovarian hyperstimulation. Minerva Ginecol 2017; 69: 225–32.
27. Yao L, Zhang W, Li H et al. The role of serum AMH and FF AMH in predicting pregnancy outcome in the fresh cycle of IVF/ICSI: a meta-analysis. Int J Clin Exp Med 2015; 8: 1755–67.
28. Ebner T, Sommergruber M, Moser M et al. Basal level of anti-Mullerian hormone is associated with oocyte quality in stimulated cycles. Hum Reprod (Oxford, England) 2006; 21: 2022–6.
29. Borges E, Braga D, Setti A et al. The predictive value of serum concentrations of anti-Mullerian hormone for oocyte quality, fertilization, and implantation. JBRA Assist Reprod 2017; 21: 176–82.
30. La Marca A, Minasi MG, Sighinolfi G et al. Female age, serum antimullerian hormone level, and number of oocytes affect the rate and number of euploid blastocysts in in vitro fertilization/intracytoplasmic sperm injection cycles. Fertil Steril 2017; 108: 777.e772–83.e772.
31. Jiang X, Yan J, Sheng Y et al. Low anti-Mullerian hormone concentration is associated with increased risk of embryonic aneuploidy in women of advanced age. Reprod Biomed Online 2018; 37: 178–83.
32. Fanchin R, Mendez Lozano DH, Frydman N et al. Anti-Mullerian hormone concentrations in the follicular fluid of the preovulatory follicle are predictive of the implantation potential of the ensuing embryo obtained by in vitro fertilization. J Clin Endocrinol Metab 2007; 92: 1796–802.
33. Majumder K, Gelbaya TA, Laing I, Nardo LG. The use of anti-Mullerian hormone and antral follicle count to predict the potential of oocytes and embryos. Eur J Obstet Gynecol Reprod Biol 2010; 150: 166–70.
34. De Conto E, Genro VK, da Silva DS et al. AMH as a prognostic factor for blastocyst development. JBRA Assist Reprod 2015; 19: 131–4.
35. Kavoussi SK, Odenwald KC, Boehnlein LM et al. Antimullerian hormone as a predictor of good-quality supernumerary blastocyst cryopreservation among women with levels <1 ng/mL versus 1–4 ng/mL. Fertil Steril 2015; 104: 633–6.
36. Lyttle Schumacher BM, Jukic AM, Steiner AZ. Anti-Mullerian hormone as a risk factor for miscarriage in naturally conceived pregnancies. Fertil Steril 2018; 109: 1065.e1–71.e1.
37. McCormack CD, Leemaqz SY, Furness DL et al. Anti-Mullerian hormone levels in recurrent embryonic miscarriage patients are frequently abnormal, and may affect pregnancy outcomes. J Obstet Gynaecol 2019; 39: 623–7.
38. Tarasconi B, Tadros T, Ayoubi JM et al. Serum anti-Mullerian hormone levels are independently related to miscarriage rates after in vitro fertilization-embryo transfer. Fertil Steril 2017; 108: 518–24.
39. Gleicher N, Kushnir VA, Sen A et al. Definition by FSH, AMH and embryo numbers of good-, intermediate- and poor-prognosis patients suggests previously unknown IVF outcome-determining factor associated with AMH. J Transl Med 2016; 14: 172.
40. Nelson SM, La Marca A. The journey from the old to the new AMH assay: how to avoid getting lost in the values. Reprod Biomed Online 2011; 23 (4): 411–20. DOI: 10.1016/j.rbmo.2011.06.011
41. La Marca A, Tolani AD, Capuzzo M. The interchangeability of two assays for the measurement of anti-Müllerian hormone when personalizing the dose of FSH in in-vitro fertilization cycles. Gynecol Endocrinol 2020; 28: 1–5. DOI: 10.1080/09513590.2020.1810659
2. Seifer DB, MacLaughlin DT, Christian BP et al. Early follicular serum mullerian-inhibiting substance levels are associated with ovarian response during assisted reproductive technology cycles. Fertil Steril 2002; 77: 468–71.
3. Depmann M, Eijkemans MJ, Broer SL et al. Does AMH Relate to Timing of Menopause? Results of an Individual Patient Data Meta-Analysis. J Clin Endocrinol Metab 2018; 103 (10): 3593–600. DOI: 10.1210/jc.2018-00724
4. Garg D, Tal R. The role of AMH in the pathophysiology of polycystic ovarian syndrome Reproductive BioMedicine Online 2016; 33 (1): 15–28.
5. La Marca A, Sighinolfi G, Radi D et al. Anti-Mullerian hormone (AMH) as a predictive marker in assisted reproductive technology (ART). Hum Reprod Update 2010; 16: 113–1305.
6. Rajpert-De Meyts E, Jorgensen N, Graem N et al. Expression of anti-Mullerian hormone during normal and pathological gonadal development: association with differentiation of Sertoli and granulosa cells.
J Clin Endocrinol Metab 1999; 84 (10): 3836–44.
7. Durlinger AL, Kramer P, Karels B et al. Control of primordial follicle recruitment by anti-Mullerian hormone in the mouse ovary. Endocrinology 1999; 140: 5789–579.
8. Sowers M, McConnell D, Gast K et al. Anti-Mullerian hormone and inhibin B variability during normal menstrual cycles. Fertil Steril 2010; 94: 1482–6.
9. Dewailly D, Gronier H, Poncelet E et al. Diagnosis of polycystic ovary syndrome (PCOS): revisiting the threshold values of follicle count on ultrasound and of the serum AMH level for the definition of polycystic ovaries. Hum Reprod 2011; 26 (11): 3123–9.
10. Lin YH, Chiu WC, Wu CH et al. Anti-mullerian hormone and polycystic ovary syndrome. Fertil Steril 2011; 96 (1): 230–5.
11. Bedenk J, Vrtačnik-Bokal E, Virant-Klun I. The role of anti-Müllerian hormone (AMH) in ovarian disease and infertility. J Assist Reprod Genet 2020; 37: 89–100.
12. Pacheco A, Cruz M, Iglesias C et al. Very low anti-mullerian hormone concentrations are not an independent predictor of embryo quality and pregnancy rate. Reprod Biomed Online 2018; 37: 113–9.
13. Sunkara SK, Rittenberg V, Raine-Fenning N et al. Association between the number of eggs and live birth in IVF treatment: an analysis of 400 135 treatment cycles. Hum Reprod (Oxford, England) 2011; 26: 1768–74.
14. Sowers MR, McConnell D, Yosef M et al. Relating smoking, obesity, insulin resistance, and ovarian biomarker changes to the final menstrual period. Ann N Y Acad Sci 2010; 1204: 95–103.
15. Dennis NA, Houghton LA, Jones GT et al. The level of serum anti-Mullerian hormone correlates with vitamin D status in men and women but not in boys. J Clin Endocrinol Metab 2012; 97 (7): 2450–5.
16. Seifer DB, Mac Laughlin D, Christian BBA et al. Early follicular serum müllerian-inhibiting substance levels are associated with ovarian response during assisted reproductive technology cycles. Fertil Steril 2002; 77 (3): 468–47.
17. Hayes E, Kushnir V, Ma X et al. Intra-cellular mechanism of anti-Mullerian hormone (AMH) in regulation of follicular development. Mol Cell Endocrinol 2016; 433: 56–65.
18. Назаренко Т.А. Эндокринные факторы женского и мужского бесплодия. Принципы гормонального лечения: монография. М., 2017.
[Nazarenko T.A. Endocrine factors of female and male infertility. Principles of hormonal treatment: monograph. Moscow, 2017 (in Russian).]
19. Broer SL, van Disseldorp J, Broeze KA et al. Added value of ovarian reserve testing on patient characteristics in the prediction of ovarian response and ongoing pregnancy: an individual patient data approach. Hum Reprod Update 2013; 19: 26–36.
20. Arce JC, La Marca A, Mirner Klein B et al. Antimullerian hormone in gonadotropin releasing-hormone antagonist cycles: prediction of ovarian response and cumulative treatment outcome in good-prognosis patients. Fertil Steril 2013; 99: 1644–53.
21. Александрова Н.В., Марченко Л.А. Современные подходы к оценке овариального резерва у женщин с преждевременной недостаточностью яичников (обзор литературы). Проблемы репродукции. 2007; 13 (2): 22–9.
[Aleksandrova N.V., Marchenko L.A. Sovremennye podkhody k otsenke ovarial'nogo rezerva u zhenshchin s prezhdevremennoi nedostatochnost'iu iaichnikov (obzor literatury). Problemy reproduktsii. 2007; 13 (2): 22–9 (in Russian).]
22. La Marca A, Sunkara SK. Individualization of controlled ovarian stimulation in IVF using ovarian reserve markers: from theory to practice. Hum Reprod Update 2014; 20: 124–40.
23. Tarlatzi TB, Venetis CA, Devreker F et al. What is the best predictor of severe ovarian hyperstimulation syndrome in IVF? A cohort study. J Assis Reprod Genet 2017; 34: 1341–51.
24. La Marca A, Sighinolfi G, Radi D et al. Anti-Mullerian hormone (AMH) as a predictive marker in assisted reproductive technology (ART). Hum Reprod Update 2010; 16: 113–30.
25. Broer SL, van Disseldorp J, Broeze KA et al. Added value of ovarian reserve testing on patient characteristics in the prediction of ovarian response and ongoing pregnancy: an individual patient data approach. Hum Reprod Update 2013; 19: 26–36.
26. Melado Vidales L, Fernandez-Nistal A, Martinez Fernandez V et al. Anti-Mullerian hormone levels to predict oocyte maturity and embryo quality during controlled ovarian hyperstimulation. Minerva Ginecol 2017; 69: 225–32.
27. Yao L, Zhang W, Li H et al. The role of serum AMH and FF AMH in predicting pregnancy outcome in the fresh cycle of IVF/ICSI: a meta-analysis. Int J Clin Exp Med 2015; 8: 1755–67.
28. Ebner T, Sommergruber M, Moser M et al. Basal level of anti-Mullerian hormone is associated with oocyte quality in stimulated cycles. Hum Reprod (Oxford, England) 2006; 21: 2022–6.
29. Borges E, Braga D, Setti A et al. The predictive value of serum concentrations of anti-Mullerian hormone for oocyte quality, fertilization, and implantation. JBRA Assist Reprod 2017; 21: 176–82.
30. La Marca A, Minasi MG, Sighinolfi G et al. Female age, serum antimullerian hormone level, and number of oocytes affect the rate and number of euploid blastocysts in in vitro fertilization/intracytoplasmic sperm injection cycles. Fertil Steril 2017; 108: 777.e772–83.e772.
31. Jiang X, Yan J, Sheng Y et al. Low anti-Mullerian hormone concentration is associated with increased risk of embryonic aneuploidy in women of advanced age. Reprod Biomed Online 2018; 37: 178–83.
32. Fanchin R, Mendez Lozano DH, Frydman N et al. Anti-Mullerian hormone concentrations in the follicular fluid of the preovulatory follicle are predictive of the implantation potential of the ensuing embryo obtained by in vitro fertilization. J Clin Endocrinol Metab 2007; 92: 1796–802.
33. Majumder K, Gelbaya TA, Laing I, Nardo LG. The use of anti-Mullerian hormone and antral follicle count to predict the potential of oocytes and embryos. Eur J Obstet Gynecol Reprod Biol 2010; 150: 166–70.
34. De Conto E, Genro VK, da Silva DS et al. AMH as a prognostic factor for blastocyst development. JBRA Assist Reprod 2015; 19: 131–4.
35. Kavoussi SK, Odenwald KC, Boehnlein LM et al. Antimullerian hormone as a predictor of good-quality supernumerary blastocyst cryopreservation among women with levels <1 ng/mL versus 1–4 ng/mL. Fertil Steril 2015; 104: 633–6.
36. Lyttle Schumacher BM, Jukic AM, Steiner AZ. Anti-Mullerian hormone as a risk factor for miscarriage in naturally conceived pregnancies. Fertil Steril 2018; 109: 1065.e1–71.e1.
37. McCormack CD, Leemaqz SY, Furness DL et al. Anti-Mullerian hormone levels in recurrent embryonic miscarriage patients are frequently abnormal, and may affect pregnancy outcomes. J Obstet Gynaecol 2019; 39: 623–7.
38. Tarasconi B, Tadros T, Ayoubi JM et al. Serum anti-Mullerian hormone levels are independently related to miscarriage rates after in vitro fertilization-embryo transfer. Fertil Steril 2017; 108: 518–24.
39. Gleicher N, Kushnir VA, Sen A et al. Definition by FSH, AMH and embryo numbers of good-, intermediate- and poor-prognosis patients suggests previously unknown IVF outcome-determining factor associated with AMH. J Transl Med 2016; 14: 172.
40. Nelson SM, La Marca A. The journey from the old to the new AMH assay: how to avoid getting lost in the values. Reprod Biomed Online 2011; 23 (4): 411–20. DOI: 10.1016/j.rbmo.2011.06.011
41. La Marca A, Tolani AD, Capuzzo M. The interchangeability of two assays for the measurement of anti-Müllerian hormone when personalizing the dose of FSH in in-vitro fertilization cycles. Gynecol Endocrinol 2020; 28: 1–5. DOI: 10.1080/09513590.2020.1810659
________________________________________________
2. Seifer DB, MacLaughlin DT, Christian BP et al. Early follicular serum mullerian-inhibiting substance levels are associated with ovarian response during assisted reproductive technology cycles. Fertil Steril 2002; 77: 468–71.
3. Depmann M, Eijkemans MJ, Broer SL et al. Does AMH Relate to Timing of Menopause? Results of an Individual Patient Data Meta-Analysis. J Clin Endocrinol Metab 2018; 103 (10): 3593–600. DOI: 10.1210/jc.2018-00724
4. Garg D, Tal R. The role of AMH in the pathophysiology of polycystic ovarian syndrome Reproductive BioMedicine Online 2016; 33 (1): 15–28.
5. La Marca A, Sighinolfi G, Radi D et al. Anti-Mullerian hormone (AMH) as a predictive marker in assisted reproductive technology (ART). Hum Reprod Update 2010; 16: 113–1305.
6. Rajpert-De Meyts E, Jorgensen N, Graem N et al. Expression of anti-Mullerian hormone during normal and pathological gonadal development: association with differentiation of Sertoli and granulosa cells.
J Clin Endocrinol Metab 1999; 84 (10): 3836–44.
7. Durlinger AL, Kramer P, Karels B et al. Control of primordial follicle recruitment by anti-Mullerian hormone in the mouse ovary. Endocrinology 1999; 140: 5789–579.
8. Sowers M, McConnell D, Gast K et al. Anti-Mullerian hormone and inhibin B variability during normal menstrual cycles. Fertil Steril 2010; 94: 1482–6.
9. Dewailly D, Gronier H, Poncelet E et al. Diagnosis of polycystic ovary syndrome (PCOS): revisiting the threshold values of follicle count on ultrasound and of the serum AMH level for the definition of polycystic ovaries. Hum Reprod 2011; 26 (11): 3123–9.
10. Lin YH, Chiu WC, Wu CH et al. Anti-mullerian hormone and polycystic ovary syndrome. Fertil Steril 2011; 96 (1): 230–5.
11. Bedenk J, Vrtačnik-Bokal E, Virant-Klun I. The role of anti-Müllerian hormone (AMH) in ovarian disease and infertility. J Assist Reprod Genet 2020; 37: 89–100.
12. Pacheco A, Cruz M, Iglesias C et al. Very low anti-mullerian hormone concentrations are not an independent predictor of embryo quality and pregnancy rate. Reprod Biomed Online 2018; 37: 113–9.
13. Sunkara SK, Rittenberg V, Raine-Fenning N et al. Association between the number of eggs and live birth in IVF treatment: an analysis of 400 135 treatment cycles. Hum Reprod (Oxford, England) 2011; 26: 1768–74.
14. Sowers MR, McConnell D, Yosef M et al. Relating smoking, obesity, insulin resistance, and ovarian biomarker changes to the final menstrual period. Ann N Y Acad Sci 2010; 1204: 95–103.
15. Dennis NA, Houghton LA, Jones GT et al. The level of serum anti-Mullerian hormone correlates with vitamin D status in men and women but not in boys. J Clin Endocrinol Metab 2012; 97 (7): 2450–5.
16. Seifer DB, Mac Laughlin D, Christian BBA et al. Early follicular serum müllerian-inhibiting substance levels are associated with ovarian response during assisted reproductive technology cycles. Fertil Steril 2002; 77 (3): 468–47.
17. Hayes E, Kushnir V, Ma X et al. Intra-cellular mechanism of anti-Mullerian hormone (AMH) in regulation of follicular development. Mol Cell Endocrinol 2016; 433: 56–65.
18. Nazarenko T.A. Endocrine factors of female and male infertility. Principles of hormonal treatment: monograph. Moscow, 2017 (in Russian).
19. Broer SL, van Disseldorp J, Broeze KA et al. Added value of ovarian reserve testing on patient characteristics in the prediction of ovarian response and ongoing pregnancy: an individual patient data approach. Hum Reprod Update 2013; 19: 26–36.
20. Arce JC, La Marca A, Mirner Klein B et al. Antimullerian hormone in gonadotropin releasing-hormone antagonist cycles: prediction of ovarian response and cumulative treatment outcome in good-prognosis patients. Fertil Steril 2013; 99: 1644–53.
21. Aleksandrova N.V., Marchenko L.A. Sovremennye podkhody k otsenke ovarial'nogo rezerva u zhenshchin s prezhdevremennoi nedostatochnost'iu iaichnikov (obzor literatury). Problemy reproduktsii. 2007; 13 (2): 22–9 (in Russian).
22. La Marca A, Sunkara SK. Individualization of controlled ovarian stimulation in IVF using ovarian reserve markers: from theory to practice. Hum Reprod Update 2014; 20: 124–40.
23. Tarlatzi TB, Venetis CA, Devreker F et al. What is the best predictor of severe ovarian hyperstimulation syndrome in IVF? A cohort study. J Assis Reprod Genet 2017; 34: 1341–51.
24. La Marca A, Sighinolfi G, Radi D et al. Anti-Mullerian hormone (AMH) as a predictive marker in assisted reproductive technology (ART). Hum Reprod Update 2010; 16: 113–30.
25. Broer SL, van Disseldorp J, Broeze KA et al. Added value of ovarian reserve testing on patient characteristics in the prediction of ovarian response and ongoing pregnancy: an individual patient data approach. Hum Reprod Update 2013; 19: 26–36.
26. Melado Vidales L, Fernandez-Nistal A, Martinez Fernandez V et al. Anti-Mullerian hormone levels to predict oocyte maturity and embryo quality during controlled ovarian hyperstimulation. Minerva Ginecol 2017; 69: 225–32.
27. Yao L, Zhang W, Li H et al. The role of serum AMH and FF AMH in predicting pregnancy outcome in the fresh cycle of IVF/ICSI: a meta-analysis. Int J Clin Exp Med 2015; 8: 1755–67.
28. Ebner T, Sommergruber M, Moser M et al. Basal level of anti-Mullerian hormone is associated with oocyte quality in stimulated cycles. Hum Reprod (Oxford, England) 2006; 21: 2022–6.
29. Borges E, Braga D, Setti A et al. The predictive value of serum concentrations of anti-Mullerian hormone for oocyte quality, fertilization, and implantation. JBRA Assist Reprod 2017; 21: 176–82.
30. La Marca A, Minasi MG, Sighinolfi G et al. Female age, serum antimullerian hormone level, and number of oocytes affect the rate and number of euploid blastocysts in in vitro fertilization/intracytoplasmic sperm injection cycles. Fertil Steril 2017; 108: 777.e772–83.e772.
31. Jiang X, Yan J, Sheng Y et al. Low anti-Mullerian hormone concentration is associated with increased risk of embryonic aneuploidy in women of advanced age. Reprod Biomed Online 2018; 37: 178–83.
32. Fanchin R, Mendez Lozano DH, Frydman N et al. Anti-Mullerian hormone concentrations in the follicular fluid of the preovulatory follicle are predictive of the implantation potential of the ensuing embryo obtained by in vitro fertilization. J Clin Endocrinol Metab 2007; 92: 1796–802.
33. Majumder K, Gelbaya TA, Laing I, Nardo LG. The use of anti-Mullerian hormone and antral follicle count to predict the potential of oocytes and embryos. Eur J Obstet Gynecol Reprod Biol 2010; 150: 166–70.
34. De Conto E, Genro VK, da Silva DS et al. AMH as a prognostic factor for blastocyst development. JBRA Assist Reprod 2015; 19: 131–4.
35. Kavoussi SK, Odenwald KC, Boehnlein LM et al. Antimullerian hormone as a predictor of good-quality supernumerary blastocyst cryopreservation among women with levels <1 ng/mL versus 1–4 ng/mL. Fertil Steril 2015; 104: 633–6.
36. Lyttle Schumacher BM, Jukic AM, Steiner AZ. Anti-Mullerian hormone as a risk factor for miscarriage in naturally conceived pregnancies. Fertil Steril 2018; 109: 1065.e1–71.e1.
37. McCormack CD, Leemaqz SY, Furness DL et al. Anti-Mullerian hormone levels in recurrent embryonic miscarriage patients are frequently abnormal, and may affect pregnancy outcomes. J Obstet Gynaecol 2019; 39: 623–7.
38. Tarasconi B, Tadros T, Ayoubi JM et al. Serum anti-Mullerian hormone levels are independently related to miscarriage rates after in vitro fertilization-embryo transfer. Fertil Steril 2017; 108: 518–24.
39. Gleicher N, Kushnir VA, Sen A et al. Definition by FSH, AMH and embryo numbers of good-, intermediate- and poor-prognosis patients suggests previously unknown IVF outcome-determining factor associated with AMH. J Transl Med 2016; 14: 172.
40. Nelson SM, La Marca A. The journey from the old to the new AMH assay: how to avoid getting lost in the values. Reprod Biomed Online 2011; 23 (4): 411–20. DOI: 10.1016/j.rbmo.2011.06.011
41. La Marca A, Tolani AD, Capuzzo M. The interchangeability of two assays for the measurement of anti-Müllerian hormone when personalizing the dose of FSH in in-vitro fertilization cycles. Gynecol Endocrinol 2020; 28: 1–5. DOI: 10.1080/09513590.2020.1810659
Авторы
Н.В. Александрова*
ФГБУ «Национальный медицинский исследовательский центр акушерства, гинекологии и перинатологии имени академика В.И. Кулакова» Минздрава России, Москва, Россия
*alexandrova.ncagip@gmail.com
Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology, Moscow, Russia
*alexandrova.ncagip@gmail.com
ФГБУ «Национальный медицинский исследовательский центр акушерства, гинекологии и перинатологии имени академика В.И. Кулакова» Минздрава России, Москва, Россия
*alexandrova.ncagip@gmail.com
________________________________________________
Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology, Moscow, Russia
*alexandrova.ncagip@gmail.com
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.